On the other hand, a small study analyzing plasma Aβ42 levels revealed no significant differences in patients taking biguanides [355], while a larger study with diabetic patients treated with metformin during early stages of AD showed higher levels of Aβ and lower levels of tau and phospho-tau in CSF [380]. This evidence concerns the gene MAPT and Alzheimer disease.